The company intends to funnel the proceeds from this market entry into its lead program, STX-1150, while simultaneously scaling its proprietary CRISPR platforms. These capital injections are slated to support ongoing research and development alongside general corporate requirements, supplementing the firm’s existing cash reserves.

Financial disclosures reveal a widening deficit for the quarter ending March 31, 2026. Scribe reported a net loss of $17.3 million, a sharp increase from the $3.4 million loss recorded during the same period the previous year. Revenue also faced significant downward pressure, dropping to $2.2 million from the $17.1 million posted twelve months earlier.